Richmond, California – October 1, 2008 – Lumiphore, Inc., a biotechnology leader in the development

of new proprietary fluorescent metal-lanthanide technology for use in high-value applications,

announced that it has signed an exclusive agreement with Biophor Diagnostics, Inc., Redwood City,

California to apply Lumiphore products in diagnostic tests for drugs of abuse.

Under the agreement, Biophor Diagnostics holds the exclusive worldwide rights to Lumi4™ technology

in current and future diagnostic tests of this type. Lumi4™ fl uorescent metal-reporter compounds

bring increased sensitivity, stability, and robustness to assays in the drugs of abuse testing market

through their excellent fade-resistant photophysical properties.

This is the third strategic partnership reached by Lumiphore in the past three years. Previous

partnerships include Cis Bio International (www.htrf.com/company/partners/) for the drug discovery

research market and Echelon Biosciences Inc. (www.echelon-inc.com) for novel cancer assays

involving phospholipid signaling and lipid-protein interactions.

The company today also announced the appointment of Dr. David J. Ecker to its board of directors.

Dr. Ecker is Chief Scientifi c Offi cer and a founder of Ibis Biosciences and a co-founder and Vice

President of Isis Pharmaceuticals. He brings to the board deep experience in successful biotech

commercialization as well as specifi c technical expertise in detection and assay platforms.

Dr. Ecker has over 24 years of experience in the pharmaceutical/biotechnology industry in cancer and

infectious disease research and development. He was a primary inventor of the Ibis T5000 biosensor

technology, and has authored more than 80 scientifi c publications and over 50 U.S. patents. His

extensive publications span biosensor technology, infectious disease research, biodefense and gene

construction/expression. His previous experience includes assistant director, Department of Molecular

Genetics at SmithKline and French (now GlaxoSmithKline).

About Lumiphore | Based in Richmond, California, Lumiphore is a biotechnology leader in the

development of proprietary fl uorescent-metal lanthanide technology for use in high-value applications

which are commercialized through market-specifi c alliances with corporate partners. Lumiphore

has exclusive licenses to the basic science developed at the University of California, Berkeley in the

laboratory of Professor Kenneth N. Raymond, a world expert on lanthanide chemistry. Metal

lanthanide reporters provide increased sensitivity for fl uorescent reagents in biology through timeresolved

detection which vastly improves assay signals over background noise. For more information

about Lumiphore, log onto www.lumiphore.com.

Press Contact

Stephen H. Blose

Lumiphore, Inc.

(415) 381-4457

Lumi4™ is a trademark of Lumiphore, Inc.